



Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Rome, Italy
18-20 September 2025

WORD OF WELCOME

Join us in Rome from 18–20 September 2025 for an enriching event that will bring together experts, clinicians, and researchers in the fields of haematology, autoimmune diseases, and SCT.

Organised by the Chronic Malignancies Working Party (CMWP) and the Autoimmune Diseases Working Party (ADWP), this event promises the latest updates and evidence-based insights crucial for advancing patient care and research.

Event Highlights Include:

1. In-depth sessions on cutting-edge topics, such as EBMT disease-specific recommendations for HCT in MDS, autoimmune disorders (AID) and CAR-T in AID, MDS diagnostics and prognostication, sequencing of therapies in myeloma, and novel cellular therapies.
2. Key presentations by renowned experts on complex subjects, including the application of artificial intelligence in haematologic disorders and novel plasma cell-targeted treatments across both myeloma and rheumatological indications.
3. Interactive case studies where participants can explore the practical applications of new treatments and horizon scanning for state-of-the-art therapies in AIDs.
4. Joint physician-nurse sessions emphasising collaborative care approaches in HCT for autoimmune and haematologic diseases.
5. Networking opportunities to foster connections with global leaders in haematology and immunology.

This event offers a unique opportunity to learn from thought leaders, gain insights into future treatments, and engage in knowledge exchange with colleagues from around the world.

Save the date and get ready to be inspired — we look forward to welcoming you in Rome!

Tobias Alexander - ADWP Chair

Donal McLornan - CMWP Chair

Elisa Roldan-Galvan - ADWP Secretary

Joanna Drozd-Sokolowska - CMWP Co-Secretary

Kavita Raj - Co-Secretary

Carmelo Gurnari - Local organiser

Raffaella Greco - Local organiser

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Rome, Italy
18-20 September 2025

Thursday, 18 September 2025

10:00 – 12:00

Scientific Business Meetings

13:00 – 13:55

Session I: Current EBMT recommendations

Chairs: Tobias Alexander (DE) & Donal McLornan (UK)

13:00 – 13:15

EBMT recommendations for HCT in MDS

Carmelo Gurnari (IT)

13:15 – 13:30

EBMT recommendations for HCT in autoimmune diseases

Elisa Roldan Galvan (UK)

13:30 – 13:45

EBMT recommendations for CART in autoimmune diseases

Raffaella Greco (IT)

13:45 – 13:55

Panel discussion

13:55 – 15:00

Session II: MDS diagnosis and prognosis

Chairs: Kavita Raj (UK) & Adriano Venditti (IT)

13:55 – 14:10

MDS in 2025: a molecular era of diagnostic and prognostic classifiers

Mario Cazzola (IT)

14:10 – 14:25

HCT or not in MDS? How to decide with current prognostic scoring systems

Nico Gagelmann (DE)

14:25 – 14:40

Are we ready for AI to help in the management of MDS?

Adrian Mosquera (ES)

14:40 – 15:00

Panel discussion

15:00 – 15:30

Coffee break

15:30 – 17:00

Session III: MDS treatment

Chairs: Fernando Barroso Duarte (BR) & Nicolaus Kröger (DE)

15:30 – 15:45

Current treatment algorithm in Lower-risk MDS

Maria Teresa Voso (IT)

15:45 – 16:00

Current treatment algorithm in Higher-risk MDS and the AML/MDS border

Amer Zeidan (US)

16:00 – 16:15

Therapeutic vulnerability in MDS/AML: looking into the future from the lab standpoint

Jaroslav Maciejewski (US)

16:15 – 16:30

Access to genomics and transplant policies in MDS in Latin-America

Gonzalo Bentolila (AR)

16:30 – 16:45

Case presentation:

Successful Second AlloSCT from Haploidentical Donor with Dosed-Reduced PTCy for MDS Relapse Refractory to HMA and DLI

Giuliano Filippini Velazquez (DE)

16:45 – 17:00

Panel discussion

17:00 – 17:30

Coffee break

17:30 – 19:00

Session IV: Autoinflammation in haematology and beyond

Chairs: Joanna Drozd-Sokolowska (PL) & Anna Paola Iori (IT)

17:30 – 17:45

VEXAS: the lynchpin between inflammation and myeloid neoplasia

Carmelo Gurnari (IT)

17:45 – 18:00

CMML and autoimmune/inflammatory conditions

Francesco Onida (IT)

18:00 – 18:15

New insights into pathophysiology, diagnosis, and treatment of Hemophagocytic Lymphohistiocytosis in adults: report from the French cohort

Coralie Bloch (FR)

18:15 – 18:30

Case presentation:

Brisk CAR-T cell expansion following ciltacabtagene autoleucel complicated by neurological changes, polymicrobial infections, and immune effector-cell-associated HLH-like syndrome

Sarah Leone (US)

18:30 – 18:45

Case presentation:

Allo-HCT in VEXAS: a global clinician experience and metanalysis

Syed Ali (AU)

18:45 – 19:00

Panel discussion

Advancements in Cellular Therapy for Autoimmune Diseases and Chronic Haematological Malignancies

Rome, Italy
18-20 September 2025

Friday, 19 September 2025

09:00 – 10:15

Joint Physician-Nurse session HCT in MDS in 2025

Chairs: *Maaïke de Ruijter (NL) & William Arcese (IT)*

09:00 – 09:15 Which donor to choose in the PtCy era?
09:15 – 09:30 Bridging or not prior to allo-HCT for MDS?
09:30 – 09:45 Conditioning regimens in the contemporary era
09:45 – 10:00 Issues on maintenance and management of relapse
10:00 – 10:15 Panel discussion

Kavita Raj (UK)
Nicolaus Kröger (DE)
Joanna Drozd-Sokolowska (PL)
Marie Robin (FR)

10:15 – 10:45

Coffee Break

10:45 – 12:15

Session V: HCT in autoinflammation and autoimmunity

Chairs: *John Snowden (UK) & Andrea Bacigalupo (IT)*

10:45 – 11:00 HCT in VEXAS
11:00 – 11:15 HCT in Behçet's disease
11:15 – 11:30 HCT in systemic sclerosis
11:30 – 11:45 HCT for AID in Brazil: Current Practices
11:45 – 12:00 *Case presentation:*
Characterising peripheral and central immune signatures in patients with aggressive multiple sclerosis treated with autologous haematopoietic stem cell transplantation or high-efficacy disease modifying treatment
12:00 – 12:15 Panel discussion

Donal McLornan (UK)
Mathieu Puyade (FR)
Nicoletta del Papa (IT)
Fernando Barroso Duarte (BR)

Gavin Brittain (UK)

12:15 – 13:15

Lunch break

13:15 – 15:00

Session VI: Plasma cells as treatment targets in haematology and autoimmune diseases

Chairs: *Patrizia Chiusolo (IT) & Paolo Muraro (UK)*

13:15 – 13:30 Novel treatment approaches in myeloma
13:30 – 13:45 Bispecifics in myeloma: bridging to CAR-T?
13:45 – 14:00 Bone marrow plasma cell landscape in health and disease
14:00 – 14:15 Plasma cell depletion in autoimmune diseases
14:15 – 14:30 *Case presentation:*
Daratumumab for relapse of autoantibody-mediated neurologic autoimmune disease following autologous hematopoietic stem cell transplantation (aHSCT)
14:30 – 14:45 *Case presentation:*
T-cell engager for autoimmune neuropathy
14:45 – 15:00 Panel discussion

Elisa Roldan Galvan (UK)
Patrick Hayden (IE)
Farzin Mashreghi (DE)
Tobias Alexander (DE)

Paulina Piesik (CA)

Jonathan Wickel (DE)

15:00 – 15:30

Coffee break

15:30 – 17:00

Session VII: Novel cellular therapies in autoimmune diseases

Chairs: *Simona Sica (IT) & Dominique Farge (FR)*

15:30 – 15:45 Bispecific antibodies in rheumatoid arthritis
15:45 – 16:00 CART in rheumatoid arthritis
16:00 – 16:15 CAR-T cell therapies in paediatric autoimmune diseases
16:15 – 16:30 iPS cells for tissue regeneration in autoimmune disease
16:30 – 16:45 *Case presentation:*
Successful treatment of difficult-to-treat ACPA-positive rheumatoid arthritis with anti-CD19 CAR T cell therapy
16:45 – 17:00 Panel discussion

Ricardo Grieshaber (DE)
Doron Rimar (IS)
Marco Becilli (IT)
Richard Burt (US)

Ioanna Minopoulou (DE)

Saturday, 20 September 2025

09:00 – 10:00 Joint Nurse-Physician session HSCT and cellular therapies for autoimmune neurologic diseases

Chairs: *Claudia Boggione (IT) & Basil Sharrack (UK)*

09:00 – 09:15 Autologous HCT in MS

Alice Mariottini (IT)

09:15 – 09:30 CAR T in MS

Lena Kristina Pfeffer (DE)

09:30 – 09:45 Cellular therapies in other neurologic indications

Tobias Hegelmaier (DE)

09:45 – 10:00 Panel discussion

10:00 – 10:35 Poster Tour

Chairs: *Tobias Alexander (DE) & Donal McLornan (UK)*

10:00 – 10:05 What essential information should be included in a patient information leaflet to effectively guide individuals with Multiple Sclerosis (MS) who are considering or undergoing autologous hematopoietic stem cell transplantation (aHSCT)?

Hannah Young (UK)

10:05 – 10:10 Anti-ROR1 CAR T cells enhanced with safety iCasp9 suicidal gene expression as novel immunotherapy for mantle cell lymphoma

Madalina Nistor (RO)

10:10 – 10:15 Role of cardiovascular risk stratification in patients undergoing autologous stem cell transplantation for multiple myeloma: a real-life, single-centre evaluation

Ambra Fumagalli (IT)

10:15 – 10:20 *An Italian cartography of VEXAS-related thrombosis: a 214.2 patient-years two-step study*

Giorgia Ranucci (IT)

10:20 – 10:25 Aggressive Systemic Mastocytosis Associated With High Risk Myelodysplastic Syndrome

Lugain Abdalla (UK)

10:25 – 10:30 The Yin and Yang of Bispecific Drugs in Multiple Myeloma

Maria Chiara Quattrocchi (IT)

10:30 – 10:35 *Comparing the MTSS and AIPSS-MF Scores for Predicting Survival After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Single-Center Experience*

Daniele Sannipoli (IT)

10:35 – 10:55 Coffee Break & Poster Tour

10:55 – 12:15 Session VIII: Immune monitoring post CART and late complications for autoimmune disease

Chairs: *Franco Locatelli (IT) & Raffaella Greco (IT)*

10:55 – 11:20 Immune monitoring post-CART

Simona Pagliuca (FR)

11:20 – 11:35 Late complications in HCT

Kirill Krigizov (RU)

11:35 – 11:50 Late complications in CART

Maeve O'Reilly (UK)

11:50 – 12:05 Secondary HLH after CART

Matteo Doglio (IT)

12:05 – 12:15 Panel discussion & take-home messages from all the organizers

WITH THANKS TO OUR SPONSORS

Gold Partner



Miltenyi Biotec

Silver Partners



Bristol Myers Squibb®

neovii

Bronze Partner



Meeting Supporter

SERVIER 
moved by you